Waldenström Macroglobulinemia Diagnosis: Questions to Ask

This page is for people newly diagnosed with Waldenström macroglobulinemia, or being tested for it. It lists questions to ask your care team and the warning signs that need fast help.

Waldenström macroglobulinemia is a slow-growing blood cancer. Doctors also call it lymphoplasmacytic lymphoma. It is a rare type of non-Hodgkin lymphoma. Blood tests, protein studies, and a bone marrow exam confirm it. These tests also show whether it affects your bone marrow, lymph nodes, spleen, or blood enough to need treatment.

Ask the clinician to write the complete diagnosis, including subtype, stage, or risk group when those terms apply. Then ask which result established it.

This cancer makes too much of a protein called IgM, short for immunoglobulin M. A blood test measuring your IgM level is central to both diagnosis and monitoring. Many people also carry a specific gene change, called MYD88. Some pathologists use it to help confirm the diagnosis. Your doctor may also test you for hepatitis C, since that infection is linked to this condition in some people.

• What tissue or blood finding confirms this diagnosis?
• What is my current IgM level, and has it been rising, stable, or falling?
• Was I tested for the MYD88 gene change, and did it come back positive?
• Was I tested for hepatitis C?
• Would review by a pathologist who regularly sees this rare lymphoma be useful?

Not everyone with Waldenström macroglobulinemia needs treatment right away. Many people with no symptoms are simply monitored over time without chemotherapy. Ask directly whether you fall into this watch-and-wait group, or whether your case calls for treatment now.

If treatment is being discussed, ask what pushed the decision. It could be symptoms, a specific IgM level, or blood test results like a low blood count. NCI lists age 70 or older, a raised beta-2-microglobulin level and a raised LDH level as other factors that point toward treatment.

A very high IgM level can thicken the blood. Doctors call this hyperviscosity syndrome, and the signs below need urgent care. If your IgM is very high, ask directly whether you are at risk, and use the guide below in the meantime.

MedlinePlus lists nosebleeds, bleeding gums, blurred vision or vision loss, dizziness and confusion among the symptoms of Waldenström macroglobulinemia. It says thickened blood is what causes problems in small vessels. Treat these signs as urgent.

• Call 911 if your sight blurs, doubles or fades suddenly, or you become confused, unsteady on your feet, drowsy in a way that is hard to shake off, or have a seizure. Thickened blood slows flow to the brain and the retina.
• Call 911 as well if you are bleeding heavily from the nose or gums and it will not stop, or you pass blood, or bleeding leaves you faint, breathless or clammy.
• Call your care team the same day if your nose bleeds repeatedly, your gums ooze, you notice a new headache that will not settle, ringing or dulled hearing, or breathlessness on mild effort. Say "Waldenström macroglobulinemia" in your first sentence so the person answering knows why it matters.

If treatment begins, ask about something called IgM rebound. NCI notes that IgM can rise after rituximab, and that combining it with certain other drugs can avoid this. Ask whether your plan carries this risk. Ask how your team plans to watch for it.

Ask where your pathology slides, bone marrow results, and blood test results are stored, and how to request them. Ask whether your current center can send them directly to another center. A second opinion does not require rejecting your first team. This cancer is rare and slow-moving. A second opinion can confirm a watch-and-wait plan or a treatment plan. It can also catch a detail worth a second look.

It is easy to hear "slow-growing" and assume a diagnosis is minor. That is not quite right here. Watch-and-wait is a deliberate strategy for people without symptoms, not a sign the cancer is being ignored. Your team is tracking specific numbers, especially your IgM level and blood counts, on a set schedule, ready to move to treatment the moment those numbers or your symptoms cross a line. Ask what that schedule looks like for you, so waiting feels like a plan rather than an open question.

Before the visit ends, write down the next test, appointment, responsible person, and expected timing. Ask how results will arrive, and who will explain them if they show up in a portal first.

The most useful outcome is a short sentence: "This is what we know, this is what we are waiting for, and this is the decision that comes next."

• National Cancer Institute — Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ)
• MedlinePlus — Waldenstrom macroglobulinemia